Literature DB >> 11942428

Neuropsychiatric aspects of Sotos syndrome. A review and two case illustrations.

S E Mouridsen1, M B Hansen.   

Abstract

Sotos syndrome, also known as cerebral gigantism, is a rare growth disorder first described by Sotos and colleagues in 1964. Since then, a majority of the literature pertaining to Sotos syndrome has focussed on the medical aspects of the syndrome, while neuropsychiatric issues have been given little attention. The present article presents a review of the current knowledge concerning neuropsychiatric aspects of Sotos syndrome. Information is provided relating to physical appearance, intellectual impairment, learning disabilities, language impairments, behavioural disorders and outcome. It is emphasised that careful delineation of neuropsychiatric aspects within a diagnostic syndrome may turn out to be the first step towards molecular characterisation of behaviour.

Entities:  

Mesh:

Year:  2002        PMID: 11942428     DOI: 10.1007/s007870200007

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


  4 in total

Review 1.  Epilepsy and Autism.

Authors:  Ashura W Buckley; Gregory L Holmes
Journal:  Cold Spring Harb Perspect Med       Date:  2016-04-01       Impact factor: 6.915

Review 2.  Cognition and Behaviour in Sotos Syndrome: A Systematic Review.

Authors:  Chloe Lane; Elizabeth Milne; Megan Freeth
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

3.  Characteristics of Autism Spectrum Disorder in Sotos Syndrome.

Authors:  Chloe Lane; Elizabeth Milne; Megan Freeth
Journal:  J Autism Dev Disord       Date:  2017-01

4.  Mutation analysis of the NSD1 gene in patients with autism spectrum disorders and macrocephaly.

Authors:  Joseph D Buxbaum; Guiqing Cai; Gudrun Nygren; Pauline Chaste; Richard Delorme; Juliet Goldsmith; Maria Råstam; Jeremy M Silverman; Eric Hollander; Christopher Gillberg; Marion Leboyer; Catalina Betancur
Journal:  BMC Med Genet       Date:  2007-11-14       Impact factor: 2.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.